

Holger Moch

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6217180/publications.pdf>

Version: 2024-02-01

294
papers

35,941
citations

8181

76
h-index

3650

180
g-index

309
all docs

309
docs citations

309
times ranked

49250
citing authors

#	ARTICLE	IF	CITATIONS
1	Novel RGAG1-BCOR gene fusion revealed in a somatic soft tissue sarcoma with a long follow-up. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 1107-1114.	2.8	4
2	Integrated Analysis Of Immunotherapy Treated Clear Cell Renal Cell Carcinomas: An Exploratory Study. Journal of Immunotherapy, 2022, 45, 35-42.	2.4	3
3	Autopsy-Based Pulmonary and Vascular Pathology: Pulmonary Endotheliitis and Multi-Organ Involvement in COVID-19 Associated Deaths. Respiration, 2022, 101, 155-165.	2.6	25
4	Detection of recurrences using serum miR-371a-3p during active surveillance in men with stage I testicular germ cell tumours. British Journal of Cancer, 2022, 126, 1140-1144.	6.4	23
5	Frequency, molecular characteristics, and therapeutic targeting of ROS1 oncogenic fusions in colorectal cancer.. Journal of Clinical Oncology, 2022, 40, 160-160.	1.6	0
6	Long-Term Persisting SARS-CoV-2 RNA and Pathological Findings: Lessons Learnt From a Series of 35 COVID-19 Autopsies. Frontiers in Medicine, 2022, 9, 778489.	2.6	18
7	Three-dimensional imaging mass cytometry for highly multiplexed molecular and cellular mapping of tissues and the tumor microenvironment. Nature Cancer, 2022, 3, 122-133.	13.2	92
8	The synergism of spatial metabolomics and morphometry improves machine learning-based renal tumour subtype classification. Clinical and Translational Medicine, 2022, 12, e666.	4.0	7
9	MALDI Mass Spectrometry Imaging-Prognostic Pathways and Metabolites for Renal Cell Carcinomas. Cancers, 2022, 14, 1763.	3.7	8
10	Updates in Grading of Renal Cell Carcinomas Beyond Clear Cell Renal Cell Carcinoma and Papillary Renal Cell Carcinoma. Advances in Anatomic Pathology, 2022, 29, 117-130.	4.3	5
11	Expanding the clinicopathological spectrum of succinate dehydrogenase-deficient renal cell carcinoma with a focus on variant morphologies: a study of 62 new tumors in 59 patients. Modern Pathology, 2022, 35, 836-849.	5.5	20
12	Morphological spectrum and molecular features of somatic malignant transformation in germ cell tumours. Histopathology, 2022, 81, 84-98.	2.9	6
13	Eosinophilic solid and cystic renal cell carcinoma and renal cell carcinomas with <i>TFEB</i> alterations: a comparative study. Histopathology, 2022, 81, 32-43.	2.9	8
14	Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study. Journal of Personalized Medicine, 2022, 12, 727.	2.5	3
15	Alterations in homologous recombination repair genes in prostate cancer brain metastases. Nature Communications, 2022, 13, 2400.	12.8	13
16	Immunohistochemical Expression Pattern of Theragnostic Targets SSTR2 and PSMA in Endolymphatic Sac Tumors: A Single Institution Case Series. Head and Neck Pathology, 2022, , .	2.6	1
17	An introduction to the WHO 5th edition 2022 classification of testicular tumours. Histopathology, 2022, 81, 459-466.	2.9	32
18	Towards a national strategy for digital pathology in Switzerland. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 481, 647-652.	2.8	7

#	ARTICLE	IF	CITATIONS
19	<scp>WHO</scp> 2022 landscape of papillary and chromophobe renal cell carcinoma. <i>Histopathology</i> , 2022, 81, 426-438.	2.9	39
20	Modified Immunoscore Improves Prediction of Survival Outcomes in Patients Undergoing Radical Cystectomy for Bladder Cancer—A Retrospective Digital Pathology Study. <i>Diagnostics</i> , 2022, 12, 1360.	2.6	3
21	Papillary renal cell carcinoma: current and controversial issues. <i>Current Opinion in Urology</i> , 2022, 32, 344-351.	1.8	11
22	The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs—Part A: Renal, Penile, and Testicular Tumours. <i>European Urology</i> , 2022, 82, 458-468.	1.9	212
23	The Role of Frozen Section Examination During Inguinal Exploration in Men with Inconclusive Testicular Tumors: A Systematic Review and Meta-analysis. <i>European Urology Focus</i> , 2021, 7, 1400-1402.	3.1	16
24	Chromophobe Renal Cell Carcinoma Aggressiveness and Immuno-oncology Therapy: How to Distinguish the Good One from the Bad One. <i>European Urology Oncology</i> , 2021, 4, 331-333.	5.4	5
25	Takotsubo Syndrome in Coronavirus Disease 2019. <i>American Journal of Cardiology</i> , 2021, 138, 118-120.	1.6	9
26	Chromophobe renal cell carcinoma: current and controversial issues. <i>Pathology</i> , 2021, 53, 101-108.	0.6	31
27	Higher prevalence of pulmonary macrothrombi in <scp>SARS-CoV</scp> than in influenza A: autopsy results from “Spanish flu” 1918/1919 in Switzerland to Coronavirus disease 2019. <i>Journal of Pathology: Clinical Research</i> , 2021, 7, 135-143.	3.0	29
28	Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Origin: Retrospective Molecular Classification Considering the CUPISCO Study Design. <i>Oncologist</i> , 2021, 26, e394-e402.	3.7	39
29	Intraductal carcinoma of the prostate is not a diagnostic entity. <i>Histopathology</i> , 2021, 78, 342-344.	2.9	6
30	Tracing Clonal Dynamics Reveals that Two- and Three-dimensional Patient-derived Cell Models Capture Tumor Heterogeneity of Clear Cell Renal Cell Carcinoma. <i>European Urology Focus</i> , 2021, 7, 152-162.	3.1	34
31	SARS-CoV-2 leads to a small vessel endotheliitis in the heart. <i>EBioMedicine</i> , 2021, 63, 103182.	6.1	93
32	Dual functions of SPOP and ERG dictate androgen therapy responses in prostate cancer. <i>Nature Communications</i> , 2021, 12, 734.	12.8	26
33	Towards a new WHO classification of renal cell tumor: what the clinician needs to know—a narrative review. <i>Translational Andrology and Urology</i> , 2021, 10, 1506-1520.	1.4	34
34	Cytoplasmic ADP-ribosylation levels correlate with markers of patient outcome in distinct human cancers. <i>Modern Pathology</i> , 2021, 34, 1468-1477.	5.5	7
35	Renal cell carcinoma pathology in 2021: “new need for renal cancer immune profiling”. <i>Current Opinion in Urology</i> , 2021, 31, 228-235.	1.8	5
36	A Challenging Task: Identifying Patients with Cancer of Unknown Primary (CUP) According to ESMO Guidelines: The CUPISCO Trial Experience. <i>Oncologist</i> , 2021, 26, e769-e779.	3.7	48

#	ARTICLE	IF	CITATIONS
37	The Tumor Profiler Study: integrated, multi-omic, functional tumor profiling for clinical decision support. <i>Cancer Cell</i> , 2021, 39, 288-293.	16.8	71
38	Spatial Distribution of Private Gene Mutations in Clear Cell Renal Cell Carcinoma. <i>Cancers</i> , 2021, 13, 2163.	3.7	10
39	HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy. , 2021, 9, e002071.		126
40	Re: Svetlana Avulova, John C. Cheville, Christine M. Lohse, et al. Grading Chromophobe Renal Cell Carcinoma: Evidence for a Four-tiered Classification Incorporating Coagulative Tumor Necrosis. <i>Eur Urol</i> 2021;79:225â€“31. <i>European Urology</i> , 2021, 80, e17-e18.	1.9	2
41	YAP1-TFE3-fused hemangioendothelioma: a multi-institutional clinicopathologic study of 24 genetically-confirmed cases. <i>Modern Pathology</i> , 2021, 34, 2211-2221.	5.5	28
42	SAMHD1 mutations in mantle cell lymphoma are recurrent and confer in vitro resistance to nucleoside analogues. <i>Leukemia Research</i> , 2021, 107, 106608.	0.8	6
43	Establishing standardized immune phenotyping of metastatic melanoma by digital pathology. <i>Laboratory Investigation</i> , 2021, 101, 1561-1570.	3.7	15
44	Whatâ€™s behind 68Ga-PSMA-11 uptake in primary prostate cancer PET? Investigation of histopathological parameters and immunohistochemical PSMA expression patterns. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 4042-4053.	6.4	47
45	Differential PD-1/LAG-3 expression and immune phenotypes in metastatic sites of breast cancer. <i>Breast Cancer Research</i> , 2021, 23, 4.	5.0	23
46	Similarities and Differences in the 2019 ISUP and GUPS Recommendations on Prostate Cancer Grading: A Guide for Practicing Pathologists. <i>Advances in Anatomic Pathology</i> , 2021, 28, 1-7.	4.3	18
47	The Morphological Spectrum of Papillary Renal Cell Carcinoma and Prevalence of Provisional/Emerging Renal Tumor Entities with Papillary Growth. <i>Biomedicines</i> , 2021, 9, 1418.	3.2	16
48	A novel 5x multiplex immunohistochemical staining reveals PSMA as a helpful marker in prostate cancer with low p504s expression.. <i>Pathology Research and Practice</i> , 2021, 228, 153667.	2.3	5
49	Probing Isoform Switching Events in Various Cancer Types: Lessons From Pan-Cancer Studies. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 726902.	3.5	4
50	Dynamic prostate cancer transcriptome analysis delineates the trajectory to disease progression. <i>Nature Communications</i> , 2021, 12, 7033.	12.8	27
51	Statistical tests for intra-tumour clonal co-occurrence and exclusivity. <i>PLoS Computational Biology</i> , 2021, 17, e1009036.	3.2	6
52	Molecular characterization and diagnostic criteria of renal cell carcinoma with emphasis on liquid biopsies. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 141-150.	3.1	14
53	Intraductal carcinoma of the prostate is an aggressive form of invasive carcinoma and should be graded. <i>Pathology</i> , 2020, 52, 192-196.	0.6	29
54	Multi-institutional re-evaluation of prognostic factors in chromophobe renal cell carcinoma: proposal of a novel two-tiered grading scheme. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 476, 409-418.	2.8	42

#	ARTICLE	IF	CITATIONS
55	Two distinct immunopathological profiles in autopsy lungs of COVID-19. <i>Nature Communications</i> , 2020, 11, 5086.	12.8	230
56	Liquid Biopsies in Renal Cell Carcinoma—Recent Advances and Promising New Technologies for the Early Detection of Metastatic Disease. <i>Frontiers in Oncology</i> , 2020, 10, 582843.	2.8	16
57	Mass Spectrometry Imaging Differentiates Chromophobe Renal Cell Carcinoma and Renal Oncocytoma with High Accuracy. <i>Journal of Cancer</i> , 2020, 11, 6081-6089.	2.5	8
58	Clonal Hematopoiesis in Hospitalized Elderly Patients With COVID-19. <i>HemaSphere</i> , 2020, 4, e453.	2.7	23
59	Novel morphological and genetic features of fumarate hydratase deficient renal cell carcinoma in <scp>HLRCC</scp> syndrome patients with a tailored therapeutic approach. <i>Genes Chromosomes and Cancer</i> , 2020, 59, 611-619.	2.8	19
60	Granular necrosis: a distinctive form of cell death in malignant tumours. <i>Pathology</i> , 2020, 52, 507-514.	0.6	20
61	HNF1 β is a sensitive and specific novel marker for yolk sac tumor: a tissue microarray analysis of 601 testicular germ cell tumors. <i>Modern Pathology</i> , 2020, 33, 2354-2360.	5.5	13
62	Electron microscopy of SARS-CoV-2: a challenging task — Authors' reply. <i>Lancet, The</i> , 2020, 395, e100.	13.7	64
63	Re: Multi-institutional Re-evaluation of Prognostic Factors in Chromophobe Renal Cell Carcinoma: Proposal of a Novel Two-tiered Grading Scheme. <i>European Urology</i> , 2020, 78, 114-116.	1.9	4
64	Harmonization and Standardization of Panel-Based Tumor Mutational Burden Measurement: Real-World Results and Recommendations of the Quality in Pathology Study. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1177-1189.	1.1	81
65	The Diabetes Gene JAZF1 Is Essential for the Homeostatic Control of Ribosome Biogenesis and Function in Metabolic Stress. <i>Cell Reports</i> , 2020, 32, 107846.	6.4	33
66	Loss of CDKN1A mRNA and Protein Expression Are Independent Predictors of Poor Outcome in Chromophobe Renal Cell Carcinoma Patients. <i>Cancers</i> , 2020, 12, 465.	3.7	21
67	ALK-rearranged renal cell carcinoma—different morphological faces of a rare tumor. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 477, 759-760.	2.8	3
68	The leading role of pathology in assessing the somatic molecular alterations of cancer: Position Paper of the European Society of Pathology. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 476, 491-497.	2.8	20
69	The single-cell pathology landscape of breast cancer. <i>Nature</i> , 2020, 578, 615-620.	27.8	582
70	Machine learning with autophagy-related proteins for discriminating renal cell carcinoma subtypes. <i>Scientific Reports</i> , 2020, 10, 720.	3.3	15
71	The landscape of viral associations in human cancers. <i>Nature Genetics</i> , 2020, 52, 320-330.	21.4	261
72	Endothelial cell infection and endotheliitis in COVID-19. <i>Lancet, The</i> , 2020, 395, 1417-1418.	13.7	5,100

#	ARTICLE	IF	CITATIONS
73	External Validation and Comparison of Prostate Cancer Risk Calculators Incorporating Multiparametric Magnetic Resonance Imaging for Prediction of Clinically Significant Prostate Cancer. <i>Journal of Urology</i> , 2020, 203, 719-726.	0.4	23
74	CDCP1 overexpression drives prostate cancer progression and can be targeted in vivo. <i>Journal of Clinical Investigation</i> , 2020, 130, 2435-2450.	8.2	27
75	The HLA Ligand Atlas: A novel immuno-oncology resource for T-cell antigen discovery.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3128-3128.	1.6	1
76	PD1 and PD-L1 Inhibitors for the Treatment of Kidney Cancer: The Role of PD-L1 Assay. <i>Current Drug Targets</i> , 2020, 21, 1664-1671.	2.1	12
77	CXCL12 expression is an adverse predictor for disease recurrence in patients with metastatic non-seminomatous testicular germ cell tumors. <i>BMC Cancer</i> , 2019, 19, 802.	2.6	4
78	<i>STRN</i> - <i>ALK</i> Rearranged Malignant Peritoneal Mesothelioma With Dramatic Response Following Ceritinib Treatment. <i>JCO Precision Oncology</i> , 2019, 3, 1-6.	3.0	21
79	Synthetic lethality between BRCA1 deficiency and poly(ADP-ribose) polymerase inhibition is modulated by processing of endogenous oxidative DNA damage. <i>Nucleic Acids Research</i> , 2019, 47, 9132-9143.	14.5	26
80	MiRNAs Are Involved in Tall Cell Morphology in Papillary Thyroid Carcinoma. <i>Cancers</i> , 2019, 11, 885.	3.7	10
81	Controversial issues in Gleason and International Society of Urological Pathology (ISUP) prostate cancer grading: proposed recommendations for international implementation. <i>Pathology</i> , 2019, 51, 463-473.	0.6	47
82	Classic Chromophobe Renal Cell Carcinoma Incur a Larger Number of Chromosomal Losses than Seen in the Eosinophilic Subtype. <i>Cancers</i> , 2019, 11, 1492.	3.7	28
83	Cancer Sample Biobanking at the Next Level: Combining Tissue With Living Cell Repositories to Promote Precision Medicine. <i>Frontiers in Cell and Developmental Biology</i> , 2019, 7, 246.	3.7	24
84	Expression and Mutation Patterns of PBRM1, BAP1 and SETD2 Mirror Specific Evolutionary Subtypes in Clear Cell Renal Cell Carcinoma. <i>Neoplasia</i> , 2019, 21, 247-256.	5.3	55
85	Histological and molecular characterization of TFEB-rearranged renal cell carcinomas. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 474, 625-631.	2.8	22
86	Allele Loss and Reduced Expression of CYCLOPS Genes is a Characteristic Feature of Chromophobe Renal Cell Carcinoma. <i>Translational Oncology</i> , 2019, 12, 1131-1137.	3.7	16
87	<i>IL6</i> and <i>CXCR1</i> expression is associated with cancer stem cell-like properties of clear cell renal cancer. <i>Journal of Pathology</i> , 2019, 248, 377-389.	4.5	32
88	Eight autopsy cases of melanoma brain metastases showing angiotropism and pericytic mimicry. Implications for extravascular migratory metastasis. <i>Journal of Cutaneous Pathology</i> , 2019, 46, 570-578.	1.3	14
89	Specific immune cell and lymphatic vessel signatures identified by image analysis in renal cancer. <i>Modern Pathology</i> , 2019, 32, 1042-1052.	5.5	16
90	Dataset for the reporting of renal biopsy for tumour: recommendations from the International Collaboration on Cancer Reporting (ICCR). <i>Journal of Clinical Pathology</i> , 2019, 72, 573-578.	2.0	4

#	ARTICLE	IF	CITATIONS
91	Preoperative assessment of CD44-mediated depth of invasion as predictor of occult metastases in early oral squamous cell carcinoma. <i>Head and Neck</i> , 2019, 41, 950-958.	2.0	32
92	Clear cell renal cell carcinoma with wild-type von Hippel-Lindau gene: a non-existent or new tumour entity?. <i>Histopathology</i> , 2019, 74, 60-67.	2.9	27
93	Data set for the reporting of carcinoma of renal tubular origin: recommendations from the International Collaboration on Cancer Reporting (ICCR). <i>Histopathology</i> , 2019, 74, 377-390.	2.9	14
94	Extensive Histological Sampling following Focal Therapy of Clinically Significant Prostate Cancer with High Intensity Focused Ultrasound. <i>Journal of Urology</i> , 2019, 202, 717-724.	0.4	46
95	Targeted next-generation-sequencing for reliable detection of targetable rearrangements in lung adenocarcinoma—a single center retrospective study. <i>Pathology Research and Practice</i> , 2018, 214, 572-578.	2.3	13
96	Morphological clues to the appropriate recognition of hereditary renal neoplasms. <i>Seminars in Diagnostic Pathology</i> , 2018, 35, 184-192.	1.5	7
97	NGS-pipe: a flexible, easily extendable and highly configurable framework for NGS analysis. <i>Bioinformatics</i> , 2018, 34, 107-108.	4.1	25
98	Somatic BRCA1 mutations in clinically sporadic breast cancer with medullary histological features. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 865-874.	2.5	5
99	Biomarker discovery for renal cancer stem cells. <i>Journal of Pathology: Clinical Research</i> , 2018, 4, 3-18.	3.0	67
100	Germinal Centers Determine the Prognostic Relevance of Tertiary Lymphoid Structures and Are Impaired by Corticosteroids in Lung Squamous Cell Carcinoma. <i>Cancer Research</i> , 2018, 78, 1308-1320.	0.9	238
101	Human Streptococcal Necrotizing Fasciitis Histopathology Mirrored in a Murine Model. <i>American Journal of Pathology</i> , 2018, 188, 1517-1523.	3.8	15
102	Microenvironmental control of breast cancer subtype elicited through paracrine platelet-derived growth factor-CC signaling. <i>Nature Medicine</i> , 2018, 24, 463-473.	30.7	120
103	Maturation of tertiary lymphoid structures and recurrence of stage II and III colorectal cancer. <i>OncImmunity</i> , 2018, 7, e1378844.	4.6	179
104	Computer-Based Intensity Measurement Assists Pathologists in Scoring Phosphatase and Tensin Homolog Immunohistochemistry Clinical Associations in NSCLC Patients of the European Thoracic Oncology Platform Lungscape Cohort. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1851-1863.	1.1	6
105	Downregulation of Autophagy-Related Proteins 1, 5, and 16 in Testicular Germ Cell Tumors Parallels Lowered LC3B and Elevated p62 Levels, Suggesting Reduced Basal Autophagy. <i>Frontiers in Oncology</i> , 2018, 8, 366.	2.8	9
106	Scavenger receptor BI promotes cytoplasmic accumulation of lipoproteins in clear-cell renal cell carcinoma. <i>Journal of Lipid Research</i> , 2018, 59, 2188-2201.	4.2	16
107	Multi-laboratory proficiency testing of clinical cancer genomic profiling by next-generation sequencing. <i>Pathology Research and Practice</i> , 2018, 214, 957-963.	2.3	11
108	Fluorocholine Transport Mediated by the Organic Cation Transporter 2 (OCT2, SLC22A2): Implication for Imaging of Kidney Tumors. <i>Drug Metabolism and Disposition</i> , 2018, 46, 1129-1136.	3.3	17

#	ARTICLE	IF	CITATIONS
109	Advancing synoptic cancer reports beyond English: the University of Bern/PathoLink approach. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 473, 655-656.	2.8	5
110	Cancer of unknown primaryâ€”Epidemiological trends and relevance of comprehensive genomic profiling. Cancer Medicine, 2018, 7, 4814-4824.	2.8	44
111	A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Modern Pathology, 2018, 31, 1770-1786.	5.5	739
112	The expression of the cancer testis antigen MAGE A4: A favorable prognostic biomarker in salivary gland carcinomas related to low tumor grading. Laryngoscope Investigative Otolaryngology, 2018, 3, 182-190.	1.5	3
113	Challenges in Pathologic Staging of Renal Cell Carcinoma. American Journal of Surgical Pathology, 2018, 42, 1253-1261.	3.7	22
114	Genomic profiling of carcinomas of unknown primary (CUP) to support clinical decisions.. Journal of Clinical Oncology, 2018, 36, e24162-e24162.	1.6	6
115	Comprehensive immunohistochemical analysis of PD-L1 shows scarce expression in castration-resistant prostate cancer. Oncotarget, 2018, 9, 10284-10293.	1.8	44
116	Glioblastoma in the era of bevacizumab: An epidemiological study in the Canton of Zurich, Switzerland, 2010-2014.. Journal of Clinical Oncology, 2018, 36, e14062-e14062.	1.6	0
117	Detecting circulating tumor DNA in renal cancer: An open challenge. Experimental and Molecular Pathology, 2017, 102, 255-261.	2.1	28
118	Prominent Oncogenic Roles of EVI1 in Breast Carcinoma. Cancer Research, 2017, 77, 2148-2160.	0.9	36
119	Tracking the origin of simultaneous endometrial and ovarian cancer by next-generation sequencing â€” a case report. BMC Cancer, 2017, 17, 66.	2.6	13
120	Detailed simulation of cancer exome sequencing data reveals differences and common limitations of variant callers. BMC Bioinformatics, 2017, 18, 8.	2.6	40
121	An Immune Atlas of Clear Cell Renal Cell Carcinoma. Cell, 2017, 169, 736-749.e18.	28.9	751
122	Computed Tomography Radiomics Predicts HPV Status and Local Tumor Control After Definitive Radiochemotherapy in Head and Neck Squamous Cell Carcinoma. International Journal of Radiation Oncology Biology Physics, 2017, 99, 921-928.	0.8	161
123	Combined mutation in Vhl, Trp53 and Rb1 causes clear cell renal cell carcinoma in mice. Nature Medicine, 2017, 23, 869-877.	30.7	101
124	Morphoproteomic Characterization of Lung Squamous Cell Carcinoma Fragmentation, a Histological Marker of Increased Tumor Invasiveness. Cancer Research, 2017, 77, 2585-2593.	0.9	15
125	A curated collection of tissue microarray images and clinical outcome data of prostate cancer patients. Scientific Data, 2017, 4, 170014.	5.3	21
126	Diagnostic criteria for oncocytic renal neoplasms: a survey of urologic pathologists. Human Pathology, 2017, 63, 149-156.	2.0	89

#	ARTICLE	IF	CITATIONS
127	Value of postmortem studies in deceased neonatal and pediatric intensive care unit patients. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 470, 217-223.	2.8	18
128	Clinical Trials for Specific Renal Cancer Subtypesâ€”The Time Will Come!. <i>European Urology Supplements</i> , 2017, 16, 241-252.	0.1	2
129	Variants and Variations in Epithelial Renal Cell Tumors in Adults: The Pathologist's Point of View. <i>European Urology Supplements</i> , 2017, 16, 232-240.	0.1	3
130	A Dual Role of Caspase-8 in Triggering and Sensing Proliferation-Associated DNA Damage, a Key Determinant of Liver Cancer Development. <i>Cancer Cell</i> , 2017, 32, 342-359.e10.	16.8	122
131	Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors. <i>Nature Medicine</i> , 2017, 23, 1046-1054.	30.7	145
132	Lack of MRE11-RAD50-NBS1 (MRN) complex detection occurs frequently in low-grade epithelial ovarian cancer. <i>BMC Cancer</i> , 2017, 17, 44.	2.6	36
133	Cytology smears as excellent starting material for nextâ€”generation sequencingâ€”based molecular testing of patients with adenocarcinoma of the lung. <i>Cancer Cytopathology</i> , 2017, 125, 30-40.	2.4	47
134	The Pros and Comms of Gene Sequencing. <i>Biomedicine Hub</i> , 2017, 2, 1-5.	1.2	1
135	Detection of <i>CCNE1/URI</i> (19q12) amplification by <i>in situ</i> hybridisation is common in high grade and type II endometrial cancer. <i>Oncotarget</i> , 2017, 8, 14794-14805.	1.8	16
136	<i>VHL</i> missense mutations in the p53 binding domain show different effects on p53 signaling and HIF1± degradation in clear cell renal cell carcinoma. <i>Oncotarget</i> , 2017, 8, 10199-10212.	1.8	11
137	Negative LC3b immunoreactivity in cancer cells is an independent prognostic predictor of prostate cancer specific death. <i>Oncotarget</i> , 2017, 8, 31765-31774.	1.8	15
138	Urinary Biomarkers for Prostate Cancer. <i>Current Drug Metabolism</i> , 2017, 18, 723-726.	1.2	3
139	Targeting the Programmed Cell Death-1 Pathway in Genitourinary Tumors: Current Progress and Future Perspectives. <i>Current Drug Metabolism</i> , 2017, 18, 700-711.	1.2	25
140	Circulating Tumor Cells: A Reliable Biomarker for Prostate Cancer Treatment Assessment?. <i>Current Drug Metabolism</i> , 2017, 18, 692-699.	1.2	7
141	Mirna Expression in Bladder Cancer and Their Potential Role in Clinical Practice. <i>Current Drug Metabolism</i> , 2017, 18, 712-722.	1.2	31
142	The maturation stage of tumoral tertiary lymphoid structures to predict recurrence risk in localized colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, e15083-e15083.	1.6	0
143	Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome. <i>Oncotarget</i> , 2016, 7, 15018-15032.	1.8	62
144	Characterization of VHL missense mutations in sporadic clear cell renal cell carcinoma: hotspots, affected binding domains, functional impact on pVHL and therapeutic relevance. <i>BMC Cancer</i> , 2016, 16, 638.	2.6	47

#	ARTICLE	IF	CITATIONS
145	Cutaneous Melanoma with Brain Metastasis: Report of 193 Patients with New Observations. PLoS ONE, 2016, 11, e0156115.	2.5	13
146	Image-based computational quantification and visualization of genetic alterations and tumour heterogeneity. Scientific Reports, 2016, 6, 24146.	3.3	28
147	Clinical impact of prostate biopsy undergrading in an academic and community setting. World Journal of Urology, 2016, 34, 1481-1490.	2.2	6
148	The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organsâ€”Part A: Renal, Penile, and Testicular Tumours. European Urology, 2016, 70, 93-105.	1.9	2,211
149	Similar lymphocytic infiltration pattern in primary breast cancer and their corresponding distant metastases. Oncolmmunology, 2016, 5, e1153208.	4.6	36
150	PDâ€1 expression is regulated by hypoxia inducible factor in clear cell renal cell carcinoma. International Journal of Cancer, 2016, 139, 396-403.	5.1	151
151	Interleukin-33 in human gliomas: Expression and prognostic significance. Oncology Letters, 2016, 12, 445-452.	1.8	29
152	The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organsâ€”Part B: Prostate and Bladder Tumours. European Urology, 2016, 70, 106-119.	1.9	1,323
153	Interleukin-33 Expression Indicates a Favorable Prognosis in Malignant Salivary Gland Tumors. International Journal of Surgical Pathology, 2016, 24, 394-400.	0.8	19
154	Hypoxia, Hypoxia-inducible Transcription Factors, and Renal Cancer. European Urology, 2016, 69, 646-657.	1.9	249
155	The IL-33/ST2 pathway contributes to intestinal tumorigenesis in humans and mice. Oncolmmunology, 2016, 5, e1062966.	4.6	80
156	L1-CAM is commonly expressed in testicular germ cell tumours. Journal of Clinical Pathology, 2016, 69, 460-462.	2.0	3
157	The Value of In Vitro Diagnostic Testing in Medical Practice: A Status Report. PLoS ONE, 2016, 11, e0149856.	2.5	125
158	Discretization of Gene Expression Data Unmasks Molecular Subgroups Recurring in Different Human Cancer Types. PLoS ONE, 2016, 11, e0161514.	2.5	4
159	MiR-99b-5p expression and response to tyrosine kinase inhibitor treatment in clear cell renal cell carcinoma patients. Oncotarget, 2016, 7, 78433-78447.	1.8	45
160	Oxygen supply maps for hypoxic microenvironment visualization in prostate cancer. Journal of Pathology Informatics, 2016, 7, 3.	1.7	10
161	Surfaceome of classical Hodgkin and nonâ€Hodgkin lymphoma. Proteomics - Clinical Applications, 2015, 9, 661-670.	1.6	19
162	Clear Cell Papillary Renal Cell Carcinoma and Renal Angiomyoadenomatous Tumor. American Journal of Surgical Pathology, 2015, 39, 889-901.	3.7	64

#	ARTICLE	IF	CITATIONS
163	Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?. PLoS ONE, 2015, 10, e0139438.	2.5	27
164	Importance of excision repair cross-complementation group 1 and ribonucleotide reductase M1 as prognostic biomarkers in malignant pleural mesothelioma treated with platinum-based induction chemotherapy followed by surgery. Journal of Thoracic and Cardiovascular Surgery, 2015, 149, 1539-1547.e1.	0.8	8
165	Functional characterization of BC039389-GATM and KLK4-KRSP1 chimeric read-through transcripts which are up-regulated in renal cell cancer. BMC Genomics, 2015, 16, 247.	2.8	15
166	Fullerenols and glucosamine fullerenes reduce infarct volume and cerebral inflammation after ischemic stroke in normotensive and hypertensive rats. Experimental Neurology, 2015, 265, 142-151.	4.1	47
167	pVHL/HIF-Regulated CD70 Expression Is Associated with Infiltration of CD27+ Lymphocytes and Increased Serum Levels of Soluble CD27 in Clear Cell Renal Cell Carcinoma. Clinical Cancer Research, 2015, 21, 889-898.	7.0	55
168	Antagonistic Cross-Regulation between Sox9 and Sox10 Controls an Anti-tumorigenic Program in Melanoma. PLoS Genetics, 2015, 11, e1004877.	3.5	85
169	CD10 expression in 325 testicular germ cell tumours. Journal of Clinical Pathology, 2015, 68, 400-403.	2.0	0
170	Tall cell papillary thyroid carcinoma: new diagnostic criteria and mutations in BRAF and TERT. Endocrine-Related Cancer, 2015, 22, 419-429.	3.1	68
171	MAGI3–AKT3 fusion in breast cancer amended. Nature, 2015, 520, E11-E12.	27.8	22
172	Interaction of tumor cells with infiltrating lymphocytes via CD70 and CD27 in clear cell renal cell carcinoma. Oncoimmunology, 2015, 4, e1049805.	4.6	8
173	Connexin 43 expression predicts poor progression-free survival in patients with non-muscle invasive urothelial bladder cancer. Journal of Clinical Pathology, 2015, 68, 819-824.	2.0	34
174	Diagnostic Accuracy of Quantitative and Qualitative Phase-Contrast Imaging for the ex Vivo Characterization of Human Coronary Atherosclerotic Plaques. Radiology, 2015, 277, 64-72.	7.3	12
175	Characterization of the 19q12 amplification including CCNE1 and URI in different epithelial ovarian cancer subtypes. Experimental and Molecular Pathology, 2015, 98, 47-54.	2.1	22
176	Chromosomal aberrations of cancer–testis antigens in myeloma patients. Hematological Oncology, 2015, 33, 159-163.	1.7	1
177	A Clearer View of the Molecular Complexity of Clear Cell Renal Cell Carcinoma. Annual Review of Pathology: Mechanisms of Disease, 2015, 10, 263-289.	22.4	175
178	Intratumor Heterogeneity in Hepatocellular Carcinoma. Clinical Cancer Research, 2015, 21, 1951-1961.	7.0	251
179	Frequent expression of PD-L1 in testicular germ cell tumors.. Journal of Clinical Oncology, 2015, 33, 379-379.	1.6	1
180	Oncotargets in Different Renal Cancer Subtypes. Current Drug Targets, 2015, 16, 125-135.	2.1	28

#	ARTICLE	IF	CITATIONS
181	Effect of MRE11 Loss on PARP-Inhibitor Sensitivity in Endometrial Cancer In Vitro. PLoS ONE, 2014, 9, e100041.	2.5	65
182	Concomitant Detection of HER2 Protein and Gene Alterations by Immunohistochemistry (IHC) and Silver Enhanced In Situ Hybridization (SISH) Identifies HER2 Positive Breast Cancer with and without Gene Amplification. PLoS ONE, 2014, 9, e105961.	2.5	22
183	Cancer testis antigen expression in testicular germ cell tumorigenesis. Modern Pathology, 2014, 27, 899-905.	5.5	22
184	miR-30c-2-3p and miR-30a-3p: New Pieces of the Jigsaw Puzzle in HIF2 β Regulation. Cancer Discovery, 2014, 4, 22-24.	9.4	14
185	Expression of histone deacetylases 1, 2 and 3 in urothelial bladder cancer. BMC Clinical Pathology, 2014, 14, 10.	1.8	61
186	<sc>KPNA2</sc> is overexpressed in human and mouse endometrial cancers and promotes cellular proliferation. Journal of Pathology, 2014, 234, 239-252.	4.5	23
187	Collecting Duct Carcinoma Versus Renal Medullary Carcinoma. American Journal of Surgical Pathology, 2014, 38, 871-874.	3.7	90
188	Biomarkers in renal cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 464, 359-365.	2.8	27
189	Reply to JÃ©rÃ©me Verine, Christophe Leboeuf and Philippe Ratajczak's Letter to the Editor re: Jimsgene Sanjmyatav, Sven Hauke, Mieczyslaw Gajda, et al. Establishment of a Multicolour Fluorescence In Situ Hybridisation-based Assay for Subtyping of Renal Cell Tumours. Eur Urol 2013;64:689-91. European Urology, 2014, 65, e71-e72.	1.9	1
190	SPOP Mutations in Prostate Cancer across Demographically Diverse Patient Cohorts. Neoplasia, 2014, 16, 14-W10.	5.3	145
191	Hif-2 β Promotes Degradation of Mammalian Peroxisomes by Selective Autophagy. Cell Metabolism, 2014, 20, 882-897.	16.2	131
192	ASPP2 controls epithelial plasticity and inhibits metastasis through β -catenin-dependent regulation of E-cadherin. Nature Cell Biology, 2014, 16, 1092-1104.	10.3	129
193	Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer. Science, 2014, 346, 85-89.	12.6	200
194	Metabolic Activation of Intrahepatic CD8+ T Cells and NKT Cells Causes Nonalcoholic Steatohepatitis and Liver Cancer via Cross-Talk with Hepatocytes. Cancer Cell, 2014, 26, 549-564.	16.8	531
195	Modelling of a genetically diverse evolution of Systemic Mastocytosis with Chronic Myelomonocytic Leukemia (SM-CMML) by Next Generation Sequencing. Experimental Hematology and Oncology, 2014, 3, 18.	5.0	5
196	MicroRNA profile of poorly differentiated thyroid carcinomas: new diagnostic and prognostic insights. Journal of Molecular Endocrinology, 2014, 52, 181-189.	2.5	86
197	An Aggressive Hypoxia Related Subpopulation of Melanoma Cells is TRP-2 Negative. Translational Oncology, 2014, 7, 206-212.	3.7	15
198	Automated Assessment of β -Cell Area and Density per Islet and Patient Using TMEM27 and BACE2 Immunofluorescence Staining in Human Pancreatic β -Cells. PLoS ONE, 2014, 9, e98932.	2.5	11

#	ARTICLE	IF	CITATIONS
199	The protein tyrosine phosphatase receptor type J is regulated by the $pVHL$ -HIF axis in clear cell renal cell carcinoma. <i>Journal of Pathology</i> , 2013, 229, 525-534.	4.5	11
200	Combined mutation of <i>Vhl</i> and <i>Trp53</i> causes renal cysts and tumours in mice. <i>EMBO Molecular Medicine</i> , 2013, 5, 949-964.	6.9	131
201	Loss of PBRM1 expression is associated with renal cell carcinoma progression. <i>International Journal of Cancer</i> , 2013, 132, E11-7.	5.1	139
202	MicroRNA Expression Array Identifies Novel Diagnostic Markers for Conventional and Oncocytic Follicular Thyroid Carcinomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, E1-E7.	3.6	99
203	Identification of Molecular Tumor Markers in Renal Cell Carcinomas with TFE3 Protein Expression by RNA Sequencing. <i>Neoplasia</i> , 2013, 15, 1231-1240.	5.3	45
204	An overview of renal cell cancer: Pathology and genetics. <i>Seminars in Cancer Biology</i> , 2013, 23, 3-9.	9.6	117
205	Comprehensive MicroRNA Expression Profiling Identifies Novel Markers in Follicular Variant of Papillary Thyroid Carcinoma. <i>Thyroid</i> , 2013, 23, 1383-1389.	4.5	117
206	Loss of SLC45A3 protein (prostein) expression in prostate cancer is associated with <i>SLC45A3</i> - <i>ERG</i> gene rearrangement and an unfavorable clinical course. <i>International Journal of Cancer</i> , 2013, 132, 807-812.	5.1	39
207	The International Society of Urological Pathology (ISUP) Grading System for Renal Cell Carcinoma and Other Prognostic Parameters. <i>American Journal of Surgical Pathology</i> , 2013, 37, 1490-1504.	3.7	639
208	The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia. <i>American Journal of Surgical Pathology</i> , 2013, 37, 1469-1489.	3.7	922
209	Renal Tumors. <i>American Journal of Surgical Pathology</i> , 2013, 37, 1518-1531.	3.7	154
210	Diagnostic and prognostic implications of the $PAX8$ - $PPAR\gamma^3$ translocation in thyroid carcinomas: a TMA -based study of 226 cases. <i>Histopathology</i> , 2013, 63, 234-241.	2.9	31
211	Tumor-associated macrophages subvert T-cell function and correlate with reduced survival in clear cell renal cell carcinoma. <i>Onc Immunology</i> , 2013, 2, e23562.	4.6	138
212	Computed Tomography Perfusion Imaging of Renal Cell Carcinoma. <i>Investigative Radiology</i> , 2013, 48, 183-191.	6.2	59
213	Analysis of BRAF and NRAS mutation status in advanced melanoma patients treated with anti-CTLA-4 antibodies: Association with overall survival?. <i>Journal of Clinical Oncology</i> , 2013, 31, 9025-9025.	1.6	4
214	Immunohistochemical detection of CD3 in T-cell lymphomas: superior sensitivity of rabbit monoclonal 2GV6 antibody compared to mouse monoclonal F7A2-38 antibody. <i>Journal of Histotechnology</i> , 2012, 35, 175-179.	0.5	2
215	Handling and reporting of nephrectomy specimens for adult renal tumours: a survey by the European Network of Uro-pathology. <i>Journal of Clinical Pathology</i> , 2012, 65, 106-113.	2.0	37
216	Integrative genome-wide expression profiling identifies three distinct molecular subgroups of renal cell carcinoma with different patient outcome. <i>BMC Cancer</i> , 2012, 12, 310.	2.6	25

#	ARTICLE	IF	CITATIONS
217	Identification and Functional Characterization of pVHL-Dependent Cell Surface Proteins in Renal Cell Carcinoma. <i>Neoplasia</i> , 2012, 14, 535-IN17.	5.3	44
218	Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. <i>Nature Genetics</i> , 2012, 44, 685-689.	21.4	1,300
219	Reliable detection of subclonal single-nucleotide variants in tumour cell populations. <i>Nature Communications</i> , 2012, 3, 811.	12.8	227
220	Diagnostic errors in the new millennium: a follow-up autopsy study. <i>Modern Pathology</i> , 2012, 25, 777-783.	5.5	56
221	Board examination for anatomical pathology in Switzerland: two intense days to verify professional competence. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2012, 461, 87-92.	2.8	4
222	Poorly differentiated oncocytic thyroid carcinoma – diagnostic implications and outcome. <i>Histopathology</i> , 2012, 60, 1045-1051.	2.9	53
223	Epidermal growth factor receptor protein expression and genomic alterations in renal cell carcinoma. <i>Cancer</i> , 2012, 118, 1268-1275.	4.1	48
224	Effect of the integrin inhibitor cilengitide on TGF-beta signaling. <i>Journal of Clinical Oncology</i> , 2012, 30, 2055-2055.	1.6	42
225	Complete remission of pulmonary metastases of Bellini duct carcinoma with cisplatin, gemcitabine and bevacizumab: a case report. <i>American Journal of Case Reports</i> , 2012, 13, 1-2.	0.8	14
226	Relevance of Periostin Splice Variants in Renal Cell Carcinoma. <i>American Journal of Pathology</i> , 2011, 179, 1513-1521.	3.8	47
227	Poorly Differentiated Thyroid Carcinomas. <i>American Journal of Surgical Pathology</i> , 2011, 35, 1866-1872.	3.7	66
228	Current Pathology Keys of Renal Cell Carcinoma. <i>European Urology</i> , 2011, 60, 634-643.	1.9	78
229	Periostin expression and epithelial-mesenchymal transition in cancer: a review and an update. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2011, 459, 465-475.	2.8	213
230	VHL mutations and dysregulation of pVHL- and PTEN-controlled pathways in multilocular cystic renal cell carcinoma. <i>Modern Pathology</i> , 2011, 24, 571-578.	5.5	55
231	VHL Gene Mutations and Their Effects on Hypoxia Inducible Factor HIF-1 α : Identification of Potential Driver and Passenger Mutations. <i>Cancer Research</i> , 2011, 71, 5500-5511.	0.9	92
232	Cystic Renal Tumors: New Entities and Novel Concepts. <i>Advances in Anatomic Pathology</i> , 2010, 17, 209-214.	4.3	67
233	A Novel Tumor Grading Scheme for Chromophobe Renal Cell Carcinoma. <i>American Journal of Surgical Pathology</i> , 2010, 34, 1233-1240.	3.7	125
234	VHL-gene Deletion in Single Renal Tubular Epithelial Cells and Renal Tubular Cysts: Further Evidence for a Cyst-dependent Progression Pathway of Clear Cell Renal Carcinoma in von Hippel-Lindau Disease. <i>American Journal of Surgical Pathology</i> , 2010, 34, 806-815.	3.7	69

#	ARTICLE	IF	CITATIONS
235	Periostin is up-regulated in high grade and high stage prostate cancer. <i>BMC Cancer</i> , 2010, 10, 273.	2.6	74
236	Expression of the extracellular matrix protein periostin in liver tumours and bile duct carcinomas. <i>Histopathology</i> , 2010, 56, 600-606.	2.9	52
237	Mining Tissue Microarray Data to Uncover Combinations of Biomarker Expression Patterns that Improve Intermediate Staging and Grading of Clear Cell Renal Cell Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 88-98.	7.0	94
238	IGFBP2 and IGFBP3 Protein Expressions in Human Breast Cancer: Association with Hormonal Factors and Obesity. <i>Clinical Cancer Research</i> , 2010, 16, 1025-1032.	7.0	57
239	Prognostic significance of epithelial-mesenchymal transition in malignant pleural mesothelioma. <i>European Journal of Cardio-thoracic Surgery</i> , 2010, 37, 566-572.	1.4	83
240	Tumor Lymphangiogenesis and Metastasis to Lymph Nodes Induced by Cancer Cell Expression of Podoplanin. <i>American Journal of Pathology</i> , 2010, 177, 1004-1016.	3.8	117
241	Patterns of Gene Expression and Copy-Number Alterations in von-Hippel Lindau Disease-Associated and Sporadic Clear Cell Carcinoma of the Kidney. <i>Cancer Research</i> , 2009, 69, 4674-4681.	0.9	370
242	Loss of VHL and Hypoxia Provokes PAX2 Up-Regulation in Clear Cell Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2009, 15, 3297-3304.	7.0	44
243	Amplification and expression of EGFR and ERBB2 in Wilms tumor. <i>Cancer Genetics and Cytogenetics</i> , 2009, 194, 88-95.	1.0	15
244	Diagnostic and Prognostic Molecular Markers for Renal Cell Carcinoma: A Critical Appraisal of the Current State of Research and Clinical Applicability. <i>European Urology</i> , 2009, 55, 851-863.	1.9	132
245	Reassessing the Current UICC/AJCC TNM Staging for Renal Cell Carcinoma. <i>European Urology</i> , 2009, 56, 636-643.	1.9	114
246	Sporadic clear cell renal cell carcinoma but not the papillary type is characterized by severely reduced frequency of primary cilia. <i>Modern Pathology</i> , 2009, 22, 31-36.	5.5	104
247	Defective Infiltration of Natural Killer Cells in MICA/B-Positive Renal Cell Carcinoma Involves β 2-Integrin-Mediated Interaction. <i>Neoplasia</i> , 2009, 11, 662-671.	5.3	54
248	Randomized Tree Ensembles for Object Detection in Computational Pathology. <i>Lecture Notes in Computer Science</i> , 2009, , 367-378.	1.3	5
249	N-glycoprotein profiling of lung adenocarcinoma pleural effusions by shotgun proteomics. <i>Cancer</i> , 2008, 114, 124-133.	4.1	50
250	pVHL and PTEN tumour suppressor proteins cooperatively suppress kidney cyst formation. <i>EMBO Journal</i> , 2008, 27, 1747-1757.	7.8	138
251	Association of cytokeratin 7 and 19 expression with genomic stability and favorable prognosis in clear cell renal cell cancer. <i>International Journal of Cancer</i> , 2008, 123, 569-576.	5.1	43
252	Prognostic Significance of Epithelial-Mesenchymal and Mesenchymal-Epithelial Transition Protein Expression in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 7430-7437.	7.0	244

#	ARTICLE	IF	CITATIONS
253	Chromophobe Renal Cell Carcinoma: Histomorphologic Characteristics and Evaluation of Conventional Pathologic Prognostic Parameters in 145 Cases. American Journal of Surgical Pathology, 2008, 32, 1822-1834.	3.7	215
254	Weakly Supervised Cell Nuclei Detection and Segmentation on Tissue Microarrays of Renal Clear Cell Carcinoma. Lecture Notes in Computer Science, 2008, , 173-182.	1.3	9
255	Xp11 Translocation Renal Cell Carcinoma in Adults: Expanded Clinical, Pathologic, and Genetic Spectrum. American Journal of Surgical Pathology, 2007, 31, 1149-1160.	3.7	381
256	Automated immunofluorescence analysis defines microvessel area as a prognostic parameter in clear cell renal cell cancer. Human Pathology, 2007, 38, 1454-1462.	2.0	44
257	pVHL and GSK3 β are components of a primary cilium-maintenance signalling network. Nature Cell Biology, 2007, 9, 588-595.	10.3	220
258	Spectrum of Epithelial Neoplasms in End-Stage Renal Disease. American Journal of Surgical Pathology, 2006, 30, 141-153.	3.7	431
259	Mutations in the tyrosine kinase domain of the EGFR gene are rare in synovial sarcoma. Modern Pathology, 2006, 19, 541-547.	5.5	38
260	Expression of Epithelial Cell Adhesion Molecule (EpCam) in Renal Epithelial Tumors. American Journal of Surgical Pathology, 2005, 29, 83-88.	3.7	96
261	Genomic alterations in renal tumours: what have we learned in the era of comparative genomic hybridisation?. Pathology, 2004, 36, 51-57.	0.6	4
262	Morphologic and Molecular Characterization of Renal Cell Carcinoma in Children and Young Adults. American Journal of Surgical Pathology, 2004, 28, 1117-1132.	3.7	253
263	Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature, 2003, 425, 307-311.	27.8	845
264	Relevance of Nuclear and Cytoplasmic von Hippel Lindau Protein Expression for Renal Carcinoma Progression. American Journal of Pathology, 2003, 163, 1013-1020.	3.8	34
265	Genetic progression of renal cell carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2002, 441, 320-327.	2.8	20
266	VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma. Journal of Pathology, 2002, 196, 186-193.	4.5	204
267	CDKN2A Mutation Analysis, Protein Expression, and Deletion Mapping of Chromosome 9p in Conventional Clear-Cell Renal Carcinomas. American Journal of Pathology, 2001, 158, 593-601.	3.8	46
268	Sarcomatoid Differentiation in Renal Cell Carcinoma. American Journal of Surgical Pathology, 2001, 25, 275-284.	3.7	467
269	Tissue microarray (TMA) technology: miniaturized pathology archives for high-throughput in situ studies. Journal of Pathology, 2001, 195, 72-79.	4.5	355
270	Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade. Journal of Pathology, 2001, 194, 349-357.	4.5	274

#	ARTICLE	IF	CITATIONS
271	Discovery of new DNA amplification loci in prostate cancer by comparative genomic hybridization. Prostate, 2001, 46, 184-190.	2.3	76
272	Genomic imbalances in the progression of endocrine pancreatic tumors. Genes Chromosomes and Cancer, 2001, 32, 364-372.	2.8	105
273	Marked genetic similarities between hepatitis B virus-positive and hepatitis C virus-positive hepatocellular carcinomas. Journal of Pathology, 2000, 192, 307-312.	4.5	58
274	Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma. Cancer, 2000, 89, 604-614.	4.1	424
275	Distance-Based Reconstruction of Tree Models for Oncogenesis. Journal of Computational Biology, 2000, 7, 789-803.	1.6	96
276	Metastatic patterns of prostate cancer: An autopsy study of 1,589 patients. Human Pathology, 2000, 31, 578-583.	2.0	1,483
277	Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma. Cancer, 2000, 89, 604-614.	4.1	2
278	Anti-neuroblastoma antibody chCE7 binds to an isoform of L1-CAM present in renal carcinoma cells. , 1999, 83, 401-408.		43
279	Cyclin D1 overexpression lacks prognostic significance in superficial urinary bladder cancer. Journal of Pathology, 1999, 188, 44-50.	4.5	45
280	Chromosomal imbalances in small cell carcinomas of the urinary bladder. , 1999, 189, 230-235.		50
281	Evaluation of the Clonal Relationship between Primary and Metastatic Renal Cell Carcinoma by Comparative Genomic Hybridization. American Journal of Pathology, 1999, 155, 267-274.	3.8	111
282	High-Throughput Tissue Microarray Analysis to Evaluate Genes Uncovered by cDNA Microarray Screening in Renal Cell Carcinoma. American Journal of Pathology, 1999, 154, 981-986.	3.8	376
283	EGF-r gene copy number changes in renal cell carcinoma detected by fluorescence in situ hybridization. , 1998, 184, 424-429.		52
284	Comparative genomic hybridization reveals frequent chromosome 13q and 4q losses in renal carcinomas with sarcomatoid transformation. , 1998, 185, 382-388.		41
285	FOCAL NEUROENDOCRINE DIFFERENTIATION LACKS PROGNOSTIC SIGNIFICANCE IN PROSTATE CORE NEEDLE BIOPSIES. Journal of Urology, 1998, 160, 406-410.	0.4	55
286	Chromosomal Imbalances in Papillary Renal Cell Carcinoma. American Journal of Pathology, 1998, 153, 1467-1473.	3.8	208
287	Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nature Genetics, 1997, 16, 68-73.	21.4	1,461
288	DNA Aneuploidy, S-phase fraction, nuclear p53 positivity, and survival in non-small-cell lung carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 1997, 431, 173-179.	2.8	19

#	ARTICLE	IF	CITATIONS
289	The Heidelberg classification of renal cell tumours. <i>Journal of Pathology</i> , 1997, 183, 131-133.	4.5	1,142
290	Altered expression of mdm-2 and its association with p53 protein status, tumor-cell-proliferation rate and prognosis in cervical neoplasia. , 1997, 74, 421-425.		27
291	Ki67 LABELLING INDEX: AN INDEPENDENT PREDICTOR OF PROGRESSION IN PROSTATE CANCER TREATED BY RADICAL PROSTATECTOMY. <i>Journal of Pathology</i> , 1996, 178, 437-441.	4.5	174
292	Comparative genomic hybridization for genetic analysis of renal oncocytomas. <i>Genes Chromosomes and Cancer</i> , 1996, 17, 199-204.	2.8	65
293	Comparative genomic hybridization for genetic analysis of renal oncocytomas. <i>Genes Chromosomes and Cancer</i> , 1996, 17, 199-204.	2.8	3
294	Heterogeneity of chromosome 17 and erbB-2 gene copy number in primary and metastatic bladder cancer. <i>Cytometry</i> , 1995, 21, 40-46.	1.8	36